Daiwa Securities Group Inc. Trims Holdings in BeiGene, Ltd. (NASDAQ:BGNE)

Daiwa Securities Group Inc. cut its position in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 87.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 172 shares of the company’s stock after selling 1,157 shares during the period. Daiwa Securities Group Inc.’s holdings in BeiGene were worth $31,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Toronto Dominion Bank lifted its stake in BeiGene by 166.4% during the third quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock worth $60,000 after purchasing an additional 208 shares during the last quarter. Knights of Columbus Asset Advisors LLC lifted its stake in BeiGene by 20.5% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 447 shares of the company’s stock worth $80,000 after purchasing an additional 76 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in BeiGene by 123.9% during the third quarter. PNC Financial Services Group Inc. now owns 732 shares of the company’s stock worth $132,000 after purchasing an additional 405 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in BeiGene by 98.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,078 shares of the company’s stock worth $194,000 after purchasing an additional 536 shares during the last quarter. Finally, Clear Harbor Asset Management LLC bought a new position in BeiGene during the fourth quarter worth $208,000. 48.55% of the stock is currently owned by institutional investors.

BeiGene Price Performance

Shares of BGNE opened at $153.58 on Monday. The firm has a market capitalization of $14.69 billion, a price-to-earnings ratio of -18.07 and a beta of 0.61. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.09 and a current ratio of 2.32. BeiGene, Ltd. has a one year low of $126.97 and a one year high of $266.67. The stock’s fifty day moving average is $154.84 and its 200-day moving average is $167.09.

BeiGene (NASDAQ:BGNE) last announced its earnings results on Monday, February 26th. The company reported ($3.53) earnings per share for the quarter, beating the consensus estimate of ($3.61) by $0.08. BeiGene had a negative return on equity of 23.12% and a negative net margin of 35.86%. The business had revenue of $634.40 million during the quarter, compared to analysts’ expectations of $632.52 million. During the same quarter last year, the business posted ($4.29) earnings per share. The company’s quarterly revenue was up 66.9% on a year-over-year basis. Equities analysts anticipate that BeiGene, Ltd. will post -8.93 EPS for the current year.

Insider Activity at BeiGene

In related news, CEO John Oyler sold 26,716 shares of the firm’s stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $148.89, for a total transaction of $3,977,745.24. Following the completion of the transaction, the chief executive officer now owns 12,084 shares of the company’s stock, valued at $1,799,186.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Julia Aijun Wang sold 397 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $167.08, for a total value of $66,330.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John Oyler sold 26,716 shares of the stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $148.89, for a total value of $3,977,745.24. Following the completion of the transaction, the chief executive officer now owns 12,084 shares of the company’s stock, valued at approximately $1,799,186.76. The disclosure for this sale can be found here. Insiders sold 64,781 shares of company stock valued at $10,222,381 over the last 90 days. 7.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BGNE. Guggenheim reduced their price objective on BeiGene from $350.00 to $345.00 and set a “buy” rating on the stock in a research note on Tuesday, February 27th. JPMorgan Chase & Co. increased their target price on BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. Sanford C. Bernstein dropped their target price on BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a research report on Wednesday, March 27th. TD Cowen increased their target price on BeiGene from $235.00 to $236.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Finally, Bank of America dropped their target price on BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research report on Monday, April 8th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $250.13.

BeiGene Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.